Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Identifieur interne : 001E58 ( Main/Exploration ); précédent : 001E57; suivant : 001E59Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Auteurs : M Mouradian [États-Unis] ; I Heuser [États-Unis] ; F. Baronti [États-Unis] ; M. Giuffra [États-Unis] ; K. Conant [États-Unis] ; T Davis [États-Unis] ; T Chase [États-Unis]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 1991-05.
Abstract
Direct acting dopamine agonists are generally less effective than levodopa in relieving symptoms of Parkinson's disease. In an attempt to quantitate and explain this situation, the acute motor responses to intravenous injections of the dopamine agonist, (-)-N-n-propyl-norapomorphine hydrochloride (NPA), were compared with those of the dopamine precursor, levodopa. At optimum dose levels, the acute anti-Parkinsonian efficacy of NPA averaged only about 50% of maximum, while essentially total symptom suppression was obtained with levodopa in patients previously treated with the amine precursor. Dyskinesia severity, however, was similar with the two drugs. These differences in anti-Parkinsonian efficacy may reflect the fact that while NPA acts mainly on D-2 dopamine receptors, levodopa results in stimulation of both the D-1 and D-2 subsets of receptors at a more physiological ratio. Future efforts to develop dopamine agonists for the treatment of Parkinsonian symptoms may thus have to consider focusing on drugs having pharmacological profile more similar to that of dopamine.
Url:
- https://api.istex.fr/document/78FD56098F13A2E7E676D3043F36C25802A5F1B1/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC488537
DOI: 10.1136/jnnp.54.5.401
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001300
- to stream Istex, to step Curation: 001300
- to stream Istex, to step Checkpoint: 001895
- to stream Main, to step Merge: 001F91
- to stream Pmc, to step Corpus: 000058
- to stream Pmc, to step Curation: 000058
- to stream Pmc, to step Checkpoint: 000309
- to stream Ncbi, to step Merge: 000191
- to stream Ncbi, to step Curation: 000191
- to stream Ncbi, to step Checkpoint: 000191
- to stream Main, to step Merge: 001F93
- to stream Main, to step Curation: 001E58
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.</title><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M" last="Mouradian">M Mouradian</name></author><author><name sortKey="Heuser, I J" sort="Heuser, I J" uniqKey="Heuser I" first="I" last="Heuser">I Heuser</name></author><author><name sortKey="Baronti, F" sort="Baronti, F" uniqKey="Baronti F" first="F" last="Baronti">F. Baronti</name></author><author><name sortKey="Giuffra, M" sort="Giuffra, M" uniqKey="Giuffra M" first="M" last="Giuffra">M. Giuffra</name></author><author><name sortKey="Conant, K" sort="Conant, K" uniqKey="Conant K" first="K" last="Conant">K. Conant</name></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T" last="Davis">T Davis</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T" last="Chase">T Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:78FD56098F13A2E7E676D3043F36C25802A5F1B1</idno><date when="1991-05-01" year="1991">1991-05-01</date><idno type="doi">10.1136/jnnp.54.5.401</idno><idno type="url">https://api.istex.fr/document/78FD56098F13A2E7E676D3043F36C25802A5F1B1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001300</idno><idno type="wicri:Area/Istex/Curation">001300</idno><idno type="wicri:Area/Istex/Checkpoint">001895</idno><idno type="wicri:doubleKey">0022-3050:1991:Mouradian M:comparison:of:the</idno><idno type="wicri:Area/Main/Merge">001F91</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC488537</idno><idno type="RBID">PMC:488537</idno><idno type="wicri:Area/Pmc/Corpus">000058</idno><idno type="wicri:Area/Pmc/Curation">000058</idno><idno type="wicri:Area/Pmc/Checkpoint">000309</idno><idno type="wicri:Area/Ncbi/Merge">000191</idno><idno type="wicri:Area/Ncbi/Curation">000191</idno><idno type="wicri:Area/Ncbi/Checkpoint">000191</idno><idno type="wicri:doubleKey">0022-3050:1991:Mouradian M:comparison:of:the</idno><idno type="wicri:Area/Main/Merge">001F93</idno><idno type="wicri:Area/Main/Curation">001E58</idno><idno type="wicri:Area/Main/Exploration">001E58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.</title><author><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M" last="Mouradian">M Mouradian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Heuser, I J" sort="Heuser, I J" uniqKey="Heuser I" first="I" last="Heuser">I Heuser</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Baronti, F" sort="Baronti, F" uniqKey="Baronti F" first="F" last="Baronti">F. Baronti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Giuffra, M" sort="Giuffra, M" uniqKey="Giuffra M" first="M" last="Giuffra">M. Giuffra</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Conant, K" sort="Conant, K" uniqKey="Conant K" first="K" last="Conant">K. Conant</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T" last="Davis">T Davis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T" last="Chase">T Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="1991-05">1991-05</date><biblScope unit="volume">54</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="401">401</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">78FD56098F13A2E7E676D3043F36C25802A5F1B1</idno><idno type="DOI">10.1136/jnnp.54.5.401</idno><idno type="href">jnnp-54-401.pdf</idno><idno type="PMID">1865201</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Direct acting dopamine agonists are generally less effective than levodopa in relieving symptoms of Parkinson's disease. In an attempt to quantitate and explain this situation, the acute motor responses to intravenous injections of the dopamine agonist, (-)-N-n-propyl-norapomorphine hydrochloride (NPA), were compared with those of the dopamine precursor, levodopa. At optimum dose levels, the acute anti-Parkinsonian efficacy of NPA averaged only about 50% of maximum, while essentially total symptom suppression was obtained with levodopa in patients previously treated with the amine precursor. Dyskinesia severity, however, was similar with the two drugs. These differences in anti-Parkinsonian efficacy may reflect the fact that while NPA acts mainly on D-2 dopamine receptors, levodopa results in stimulation of both the D-1 and D-2 subsets of receptors at a more physiological ratio. Future efforts to develop dopamine agonists for the treatment of Parkinsonian symptoms may thus have to consider focusing on drugs having pharmacological profile more similar to that of dopamine.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Mouradian, M M" sort="Mouradian, M M" uniqKey="Mouradian M" first="M" last="Mouradian">M Mouradian</name></region><name sortKey="Baronti, F" sort="Baronti, F" uniqKey="Baronti F" first="F" last="Baronti">F. Baronti</name><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T" last="Chase">T Chase</name><name sortKey="Conant, K" sort="Conant, K" uniqKey="Conant K" first="K" last="Conant">K. Conant</name><name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T" last="Davis">T Davis</name><name sortKey="Giuffra, M" sort="Giuffra, M" uniqKey="Giuffra M" first="M" last="Giuffra">M. Giuffra</name><name sortKey="Heuser, I J" sort="Heuser, I J" uniqKey="Heuser I" first="I" last="Heuser">I Heuser</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:78FD56098F13A2E7E676D3043F36C25802A5F1B1
|texte= Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
}}
| This area was generated with Dilib version V0.6.19. |  |